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Rapid Direct Sequence Analysis of the Dystrophin Gene
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Departments of 1Neurology, 2Human Genetics, 3Pathology, and 4Pediatrics, University of Utah, Salt Lake City, and 5Department of Neurology,
Ohio State University, Columbus
Mutations in the dystrophin gene result in both Duchenne and Becker muscular dystrophy (DMD and BMD), as
well as X-linked dilated cardiomyopathy. Mutational analysis is complicated by the large size of the gene, which
consists of 79 exons and 8 promoters spread over 2.2 million base pairs of genomic DNA. Deletions of one or
more exons account for 55%–65% of cases of DMD and BMD, and a multiplex polymerase chain reaction
method—currently the most widely available method of mutational analysis—detects ∼98% of deletions. Detection
of point mutations and small subexonic rearrangements has remained challenging. We report the development of
a method that allows direct sequence analysis of the dystrophin gene in a rapid, accurate, and economical fashion.
This same method, termed “SCAIP” (single condition amplification/internal primer) sequencing, is applicable to
other genes and should allow the development of widely available assays for any number of large, multiexon genes.
Introduction
The dystrophinopathies—Duchenne muscular dystro-
phy (DMD [MIM 310200]) and Becker muscular dys-
trophy (BMD [MIM 300376])—are the most common
inherited disorders of muscle. Although reliable preva-
lence data are lacking, the prevalence of DMD is gen-
erally estimated at 1:3,500 live male births (Emery
1991). Both DMD and BMD are due to mutations in
the dystrophin gene (MIM 300377), located at Xp21,
which comprises 79 exons and 8 tissue-specific pro-
moters distributed across ∼2.2 Mb of genomic se-
quence—making dystrophin the largest gene yet de-
scribed. Dystrophin gene deletions are found in ∼55%
of patients with BMD and 65% of patients DMD; point
mutations account for ∼30% of mutations, and dupli-
cations account for the remainder (Miller and Hoffman
1994). Genetic testing for deletions relies on a multiplex
PCR technique, with amplification of fragments con-
taining 18–25 of the gene’s 79 exons (Beggs et al. 1990;
Chamberlain et al. 1990) and with deletions detected as
absent or size-shifted bands on agarose gel analysis. Be-
cause deletions tend to occur in “hotspots” within the
dystrophin gene, analysis of this limited number of exons
can detect 98% of dystrophin deletions.
Testing for dystrophin point mutations has been
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available only on a research basis, from specialized lab-
oratories. Such analysis requires sequencing of all 79
exons and 8 promoters; there are no particularly com-
mon point mutations or point mutation hotspots, and
each affected family may carry a unique mutation in
this enormous gene (termed “private mutations” be-
cause they are exclusive to individual families). Instead
of direct sequence analysis, some research laboratories
perform point mutation analysis on cDNA derived by
RT-PCR from muscle mRNA. As an alternative, other
laboratories have utilized the protein truncation test
(PTT), which may be performed using peripheral blood
lymphocyte DNA (Roest et al. 1993) but often uses
mRNA derived from muscle biopsy (Tuffery-Giraud et
al. 1999). There is an obvious drawback to approaches
that require muscle biopsy, an invasive procedure with
a generally accepted risk of complications (e.g., bleed-
ing, infection, and hematoma formation) of ∼1%, and
one that may often be associated with psychological
distress for children.
Because direct sequence analysis of the dystrophin
gene has been considered too labor intensive, expensive,
and time consuming (Bennett et al. 2001), several
groups have recently developed strategies to detect ex-
onic sequence variations by use of screening methods
followed by direct sequence analysis of variant frag-
ments only. One of these strategies is based on SSCP
analysis (Mendell et al. 2001). This strategy, termed
“DOVAM-S” (detection of virtually all mutations–
SSCP) relies on multiplexing as many as 23 amplicons
per lane, with SSCP in as many as five conditions. The
authors report that as many as 75% of nondeletion
mutations may be detected by this method, but there
are several drawbacks. One is that all band variations
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Figure 1 Agarose gel analysis of primary PCR products. An aliquot of each well from the 96-well PCR amplification plate is loaded in
a 96-well format onto an agarose gel. Electrophoretic separation distance for each band is ∼1.8 cm, because the wells are angled slightly in
relation to the migration path. The products are from a patient with a multiexon deletion who is missing exons 20–30 and the DMD260
promoter. Products corresponding to exons 1–78 are located in sequential wells, starting left to right and top to bottom, followed by the multiple
exon 79 and alternate promoter products. Note the absence of products in wells corresponding to exons 20–30 and to Dp260.
detected by SSCP techniques still need to be sequenced
to determine whether they represent pathogenic muta-
tions; the dystrophin gene, because of its size, has many
reported polymorphisms. Another drawback is that, for
economies of scale in the use of reagents and technician
time, individual samples may need to be saved until
multiple samples are available for simultaneous analysis
of band variation.
A second strategy relies on denaturing high-perform-
ance liquid chromatography (DHPLC) as a screening
method (Bennett et al. 2001). This strategy screens for
DNA variations by separating heteroduplex and homo-
duplex DNA fragments by reverse-phase liquid chro-
matography, again followed by direct sequence analysis
of variant amplicons. Using this method, Bennett et al.
(2001) detected point mutations in six of eight DNA
samples from patients without deletions, and those au-
thors argued for its use, on the basis of both economic
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and scientific concerns. Another alternative includes
double gradient, denaturing gradient gel electrophoresis
(DGGE) (Cremonesi et al. 1997). A drawback to all
such approaches is that they are screening methods,
with limitations in sensitivity inherent in each under-
lying technique. Each can detect both mutations and
non–disease-associated polymorphisms, and a further
sequencing step is required to distinguish between these
possibilities.
We have developed a method that allows for the
rapid, accurate, and economical analysis of any large
multiexon gene. This method, single condition ampli-
fication/internal primer (SCAIP) sequencing, relies on
amplification of a large number of exons at a single set
of PCR temperatures. Sequencing specificity is gained
by uniform use of a second, internal set of sequencing
primers. Sufficient sequencing specificity is obtained
without optimization of individual amplicon condi-
tions. In the case of the dystrophin gene, our method
results in complete double-stranded sequencing cover-
age of all known coding regions and in seven of the
eight tissue-specific promoters. This sequencing can be
routinely performed within three working days (follow-
ing DNA purification) at a reasonable cost (including
both reagents and personnel costs). Although the dys-
trophin muscle mRNA consists of 14 kb, our method
analyzes an average of nearly 110 kb of sequence, al-
lowing detection of polymorphisms in flanking intronic
regions, as well as the 3′ and 5′ UTRs. In addition, our
method allows detection of the ∼2% of patients with
exonic deletions not detected by the widely available
multiplex PCR technique.
Patients and Methods
Patients
We ascertained patients from the University of Utah’s
Muscular Dystrophy Association clinic. The diagnosis
of a dystrophinopathy was determined by the presence
of clinical features consistent with DMD or BMD, along
with either (1) absent or altered dystrophin expression,
as determined by immunohistochemical, immunoflu-
orescent, or immunoblot analysis or (2) a clear X-linked
family history. Some patients had previously had con-
firmation of dystrophin deletions by clinical testing. Pro-
bands from 42 families were enrolled; 41 were male
individuals with dystrophinopathy, according to the
above criteria, and the remaining proband was a woman
who was an obligate carrier (and the mother of two
deceased patients with DMD). She had adult-onset limb-
girdle weakness, which led to wheelchair dependence in
her sixth decade. Nine additional DNA samples were
obtained from self- or physician-referred patients na-
tionwide who had been shown to be deletion negative
on standard screening.
Patients were catalogued according to whether they
harbored large-scale dystrophin deletions detectable by
standard clinical multiplex PCR analysis. Blood samples
for DNA analysis were obtained, according to a protocol
approved by the institutional review boards of partici-
pating institutions, from patients who either had no clin-
ical record of testing for dystrophin deletion (unknown
deletion status) or who had no detectable deletion by
commercial testing. DNA was obtained from each blood
sample, using a salting-out method (PureGene, Gentra
Systems).
Direct sequence analysis was also performed on 66
DNA samples from one clinical center (Ohio State Uni-
versity [OSU]). Of these, 64 had been previously eval-
uated by the DOVAM-S technique. The clinical phe-
notype of this set of patients was confirmed by one
investigator (J.M.).
SCAIP Sequencing
The genomic organization of the dystrophin gene
was assembled from contigs downloaded from the
UCSC Genome Bioinformatics Web page (Kent et al.
2002) (see also the International Human Genome Se-
quencing Consortium 2001 [Lander et al. 2001]). As-
sembly and exon-intron annotation was performed us-
ing task-specific Perl scripts. Our assembly reveals that
the DMD region is currently contiguous and gap free
for the dystrophin Dp427m muscle isoform (accession
number NM_0040006.1) spanning 2.09 Mb, and the
dystrophin Dp427c brain isoform (accession number
NM_000109) spanning 2.22 Mb of chromosome
Xp21.2. Primer systems for PCR were designed to am-
plify DNA fragments, which span each exon and seven
of the eight promoters (Dp427m, Dp427p, Dp427c,
Dp427l, Dp260, Dp140, and Dp116). Each amplicon
was designed for an optimal size range of 1.2–1.4 kb,
with the exon, including unique promoters, centered
within the amplicon (with the exception of exon 79,
which was broken into seven fragments) to maintain
uniform conditions. These were designed to produce 93
amplicons with a nearly universal size; this uniformity
allows us to predict likely amplification conditions, using
a single set of PCR temperatures. Aliquots (15 pmol) of
each primer are placed into individual wells of a 96-well
tray, evaporated to dryness in a speed vacuum system,
and stored in a freezer at 20C until use. For PCR
amplification, 10 mg of patient template DNA is ali-
quoted into a master PCR mixture, and, subsequently,
25 ml of the mixture is aliquoted into the 96-well dish
with dry primers. PCR amplifications were performed
using the Platinum Taq DNA Polymerase High Fidelity
System (Invitrogen), and each 25 ml of aliquoted reaction
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contained 100 ng of genomic DNA, 200 mM dNTPs, 15
pmol of each PCR primer, 1# reaction buffer, 2 mM
Mg2SO4, and 0.5 U Taq DNA polymerase. PCR is per-
formed in a thermocycler for 25 cycles under the fol-
lowing conditions: denaturation at 94C for 20 s, an-
nealing at 55C for 30 s, and extension for 68C for 4
min, followed by a final extension at 68C for 7 min.
To validate PCR amplification and detect any dele-
tions, 3 ml of the PCR reaction is run on a .75% agarose
gel/ethidium bromide gel. The resulting gel is photo-
graphed and analyzed for absence of one or more bands.
Because the absence of a single band may result from a
primer site polymorphism, PCR is repeated, in such
cases, using each of the following: the same primers, the
internal sequencing primers, and combinations of orig-
inal and internal primers. The absence of more than one
adjacent exon is interpreted as being consistent with a
multiexon deletion. The PCR products are then trans-
ferred and bound to a 96-well filter plate (MAFBN0B10;
Millipore), with a 1.0-mm glass fiber type B filter, in the
presence of a 5 M guanidine HCl/potassium acetate so-
lution. Four 80% ethanol washes remove unincorpor-
ated primers, nucleotides, and excess salt and are fol-
lowed by an elution of the fragments with warm
nanopure H2O.
Internal sequencing primers were designed to anneal
to unique intronic flanking sequences, with attention to
the specific 3′ sequence for each primer. As with the PCR,
the primers are stored in 384-well plates so that both
PCR set-up and sequence reaction set-up can be done
with multichannel pipettors and pipetting robots. The
sequence reactions are assembled by transfer of 6 ml of
PCR product, along with 10 pmol of sequencing primer,
to 2 wells of a 384-well cycle-sequencing plate, and the
samples with primers are evaporated to dryness in a
speed vacuum system. The fragments are then rehy-
drated with a 5-ml mixture of 0.5 ml ABI Prism BigDye
terminators (version 3.0), 0.75 ml 5# buffer mix, and
3.75 ml nanopure H2O; the plates are heat-sealed with
foil and are placed on thermocycling blocks for cycle
sequencing. Cycling conditions included an initial de-
naturation at 96C for 30 s, followed by 46 cycles at
96C for 10 s, 50C for 5 s, and 60C for 4 min. Upon
completion of cycle sequencing, 20 ml of 62.5% ethanol/
1M potassium acetate (pH 4.5) was added to each re-
action, and the sequence plates were centrifuged at 4,000
rpm at 4C for 45 min. The samples were resuspended
in 15 ml of HiDi formamide (ABI) and were electropho-
resed on an ABI 3700 DNA analyzer prepared with POP-
5 capillary gel matrix. All plates within the system have
bar code labels with plain sample identifiers on them.
These bar codes are captured at multiple steps of the
process, using a Web-based system for plate tracking.
Sequence Analysis
After initial data processing on the ABI 3700 instru-
ments, sequence-trace files are transferred onto a Linux
disk server. The base calls are reanalyzed with the Phred
program (Ewing et al. 1998), which adds a quantitative
base-quality value. This base-quality value provides a
probabilistic estimate of the correctness of the base call.
The quality values are the log of the probability that the
base call is correct, such that a Phred value of 20 cor-
responds to a 99% probability that the base call is ac-
curate, and a Phred value of 30 corresponds to a 99.9%
probability that the base call is accurate. The sequence
is assembled with dystrophin consensus sequence, using
the Phrap program (Ewing and Green 1998), and po-
tential mutations are identified using the Consed pro-
gram (Gordon et al. 1998). The read assembly is done
on a per-PCR-fragment basis, and a single PCR Phrap
assembly will consist of the consensus genomic sequence
and all sequence reads relating to the PCR. The read
sequence and Phred quality values are compared with
the assembled consensus sequence using Cross_match
(Ewing and Green 1998), and all discrepancies are
tagged and ranked according to the Phred quality of the
base (cutoff of 15). All PCR assemblies (reads plus con-
sensus sequence and tagged discrepancies) are then com-
piled into one Consed project for review. Potential base
discrepancies are catalogued using Perl scripts, and the
discrepancies undergo human review of original trace
files. This final list of reviewed discrepancies is loaded
into an Oracle database, where they can then be further
reviewed in a Web browser.
Nucleotide sequence position is based on the anno-
tated mRNA sequence, found in GenBank (accession
number NM_0040006.1), that encodes the dystrophin
Dp427m isoform. The oligonucleotide sequences of
primers used in amplification and sequencing of the dys-
trophin gene are available in supplementary tables A and
B (online only).
Results
Large-Scale (1 Exon) Deletions
Deletion status was determined by reviewing clinic
records or obtaining results of clinical (multiplex PCR)
testing in 42 Utah probands. Large-scale deletions were
found in 25/42 (59.5%) patient samples. (As discussed
below, a single Utah sample had a nonhotspot single-
exon deletion, bringing the total found in the Utah
cohort to 26/42 [62%] probands.) SCAIP sequence anal-
ysis was not performed in individuals with these large-
scale deletions.
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Figure 2 Average Phrap score coverage of DMD exons and promoter regions. Each block represents the length of the individual PCR
products, with the exonic sequence indicated by the thick line on the top horizontal axis. The average Phrap score observed in the present
study is plotted along its horizontal position, with the vertical axis ranging from Phrap score 15 to 50. Phrap scores 150 are not shown, and
the portions of the plot corresponding to the exons 100 nt are indicated in gray.
Direct Sequence Analysis by SCAIP Sequencing
Amplification efficiency and deletion detection.—In
anticipation of direct sequence analysis, PCR amplifi-
cation was performed on 94 samples. These included the
remaining 17 Utah probands without multiplex dele-
tions and the 9 referral samples (total number of unique
families is 26), 2 relatives of Utah probands (1 asymp-
tomatic carrier mother and 1 affected sibling), and 66
samples from OSU (64 DOVAM-screened and 2 un-
screened). Thus, PCR amplification was performed on
a total of 94 specimens.
Analysis of PCR products by visualization on agarose
gels resulted in the identification of three individuals
with deletions1 exon. In one proband studied at OSU,
multiple amplification products from adjacent exons (the
DMD260 promoter and exons 20–30 [fig. 1]) were miss-
ing; review of records (which were unblinded only after
the entire sample set was analyzed) showed that this had
been detected by DOVAM analysis. In two patients, sin-
gle amplification products were not present in exons not
screened in commonly used multiplex screening sets; in
each case, PCR was repeated with internal primers, to
exclude the presence of polymorphisms at the primer
sites, and the absence of a product on the second round
of amplification was interpreted as representing single
exon deletions. One Utah patient had a deletion of exon
18. One OSU patient had a deletion of exon 21; un-
blinded postamplification review of the DOVAM results
showed that a possible deletion had been suspected but
that a primer site polymorphism could not be excluded.
A total of 8,742 PCR analyses were performed (94
individuals# 93 PCRs each); this number of analyses
excluded exons determined to be deleted in these three
patients (14 deleted exons, leaving 8,728 potential
products), the efficiency of primary PCR recovery (de-
fined as the presence of a band on first pass, using single-
plate amplification) was 8,716/8,728 (99.86%).
Sequencing efficiency and quality.—Sequencing was
not performed on samples from the three patients in
whom deletions were detected; therefore, direct sequence
analysis was performed on 91 individual patient samples
(91# 93 exonsp 8,463 exons sequenced). The overall
quality of sequence recovery is shown in figure 2. The
Phrap score over coding regions of the gene is generally
160. The efficiency of primary sequencing recovery (de-
fined as high quality sequence on the first sequencing
reaction) was 8,396/8,463 (99.21%).
Mutation and polymorphism detection.—Among the
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samples from the 16 Utah probands and 9 referral sam-
ples, mutations were detected by SCAIP sequence anal-
ysis in 16; 5 additional samples harbored duplications
(see below), resulting in an overall detection efficiency
of 80% in this group (16/20 patients without duplica-
tions). The mutations are summarized in tables 1 and 2
and include 10 stop codon mutations, 1 single-base-pair
insertion, and 1 single-base-pair deletion. The single-
base-pair insertions and deletions were easily detectable
as mixed base calls in the two females tested.
In two referral samples, we detected sequence varia-
tions that may cause disease by altering intronic splice
signals. One is a highly likely cause of disease, because
it occurs in the highly conserved 1 position in intron
25 (changing a G to a C). The other is less definitively
causative, because it occurs in the less conserved 9
position in intron 11. Both are unique in our series
( ) and are previously unreported, according tonp 91
the Leiden database of dystrophin mutations. Definitive
assignment of a causative status to these two mutations
will require analysis of dystrophin transcripts; at present,
muscle samples are unavailable to us, although further
studies are planned.
Of particular interest are two substitutions that result
in nonsynonymous changes in amino acid sequence in
highly conserved functional domains of the dystrophin
protein. One of these, in a boy with a DMD phenotype
(loss of ambulation at age 10 years) substitutes a phe-
nylalanine for a cysteine in the dystroglycan-binding do-
main, in a residue conserved in the dystrophin protein
through Caenorhabditis elegans. The second, in a boy
with a BMD phenotype (still ambulant at age 16 years),
substitutes a valine for an asparagine at a similarly con-
served residue in the actin-binding domain.
After direct sequence analysis was performed, dystro-
phin duplication analysis was performed in 13 samples,
including the 9/25 Utah or referral samples without de-
tectable mutations, and the 4 with presumed mutations
discussed above (2 intronic and 2 missense). Duplication
analysis was performed using the multiplex amplifiable
probe hybridization (MAPH) technique (White et al.
2002). No duplications were detected in the samples
with the four presumed mutations. Of the remaining
nine samples, duplications were found in five (data not
shown). Of the four remaining patients without detected
mutations, one individual (patient 42965) was reported
to have dystrophin of an increased molecular weight
when analyzed with the use of commercially obtained
immunoblots, raising the possibility that a duplication
remains undetected by the MAPH technique. Our strat-
egy is not currently optimized for the detection of du-
plications in agarose gels, because (1) detection by tem-
plate dosage is qualitative, not quantitative, after 25
cycles of PCR amplification, reaching a nonexponential
phase of PCR; and (2) detection by altered band size
would require duplications to occur within the 1.1–1.3
kb of sequence contained within the primary amplifi-
cation product, which would be expected to be a rare
event.
Comparison of sensitivity to DOVAM.—Using SCAIP,
we studied 66 samples from a second center, in a blinded
fashion; 64 had previously been studied by DOVAM,
which detected subexonic mutations in 44 samples and
possible exonic deletions in 2 (discussed above). SCAIP
analysis detected all 44 mutations, as well as a previously
undetected stop codon mutation (Glu2035X in exon 42,
GAG:2035:TAG) in 1 of the 20 other nondeleted sam-
ples. This position is 2 nucelotides (nt) 5′ of a common
variant, GAT:2035:GAG (Asp:Glu), that may have in-
terfered with the SSCP analysis used in the DOVAM
test.
Discussion
We describe the initial application of the SCAIP se-
quencing method to mutational analysis of the dystro-
phin gene. This method has a sensitivity at least equal
to that of DOVAM screening, and it detected at least
one mutation not detected by the DOVAM method. It
gives highly reproducible and accurate results and can
be performed economically on single samples. Overall,
SCAIP detected dystrophin mutations in 70% of patient
samples that did not have deletions of 1 exon. When
five patients with duplications from the Utah/referral set
were excluded, the detection increased to 73% (61/84).
This is probably an underestimate of the actual rate of
detection in the general nonduplication sample popu-
lation, because duplication testing was not performed
on the DOVAM-negative/SCAIP-negative set ( ).np 17
Attempts to correlate these numbers with the general
dystrophinopathy population are unhelpful, because
our patient set was not a random sample; it likely rep-
resented a population enriched in duplications, stop co-
dons, and subexonic rearrangements (to judge by the
referral samples). The absence of detectable mutations
in the remaining patients is not yet explained; however,
the situation is unlike the one produced when DOVAM
or DHPLC screening is performed, in that we can state
unequivocally that the known coding regions of the dys-
trophin gene do not contain disease-causing subexonic
mutations.
The primary determinant of sequence specificity and
base-call quality is the uniform use of internal sequenc-
ing primers. The assay design is robust, in that it can
tolerate secondary, nonspecific PCR amplification prod-
ucts, as opposed to assays that use a single set of primers
or use secondary primers to universal sequences on the
5′ end of the PCR primers. An original design criterion
was to optimize a single 96-well–plate assay, in which
all coding regions and promoters of the dystrophin gene
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Table 2
Summary of Mutation Detection in Nondeleted,
Nonduplicated Probands
Sample
No. of
Mutations
No. of Samples
(% with Mutation)
Utah samples/referrals 16 20 (80)
DOVAM positive 44 44 (100)
DOVAM negative 1 18 (5)
Unscreened by DOVAM 0 2 (0)
Total 61 84
could be amplified on a single PCR plate. The PCR
products are then to be purified in plate format, using
multichannel pipetting robots, and two cycle sequencing
plates are prepared and processed. The one patient–one
plate assay is designed to meet the requirements of both
a rapid turnaround time for the assay and the ability
to scale the assay in response to increasing demand.
Phenotype/Genotype Correlations
The rapid and economical detection of stop codons
and small rearrangements will facilitate the study of se-
quence context effects on disease expression. However,
in the present study, only limited correlations between
phenotype and genotype are to be drawn, although our
results raise several interesting examples. One patient
with BMD—the most mildly affected patient in the Utah
group, who is still walking at age 58 years—has a mu-
tation resulting in a premature stop signal in the third
amino acid of the muscle isoform; the next methionine
is at position 124. Another intriguing result is the pres-
ence, in our relatively small sample, of two stop codon
mutations in exon 31, both resulting in the BMD phe-
notype. Although stop codon mutations are expected to
be essentially randomly distributed across the gene (un-
like the hotspots found for exonic deletions) (Roberts et
al. 1994), the presence of two exon 31 stop codon mu-
tations raises the possibility that stop codons in certain
exons may predispose to a milder phenotype, perhaps
because of the influence of such mutations in promoting
exon skipping (as seen in the mdx mouse [Wilton et al.
1997; Lu et al. 2000]). Further studies are planned to
determine the mRNA and protein sequences in these and
other patients.
Two patients had a previously undescribed Gln1565X
mutation. These patients are not known to be related,
and analysis of SNPs reveals different haplotypes over
at least a portion of the dystrophin gene, supporting the
idea that they are unrelated (although distant relatedness
with intragenic recombination cannot be excluded). This
example illustrates one of the additional advantages of
SCAIP analysis. That is, SNPs are found throughout the
gene; some are quite common, others less so. With the
use of SCAIP analysis—unlike the use of screening strat-
egies, such as SSCP or DHPLC—a sequence variation
can be immediately identified with certainty, and the
frequency of such variations can be quickly established
by comparison with our large and growing database
of specific polymorphisms. By cataloging these SNPs
throughout the dystrophin gene’s coding and control
regions, and establishing a rigorous and standardized
phenotyping process, we expect to generate testable hy-
potheses regarding the role of such SNPs in the presen-
tation and/or progression of disease. For example, poly-
morphisms in the primary cardiac or brain isoform
promoters could conceivably alter the clinical expression
of cardiomyopathy or cognitive dysfunction. Studies to
address these possibilities are under way.
Implications for Clinical Use, Including Genetic
Counseling
Application of this method to the study and clinical
care of dystrophin-related diseases will obviate the need
for muscle biopsy in a large number of patients. It will
routinely allow rapid detection, in an economical fash-
ion, of the following gene variations in patients with
dystrophinopathy: (1) all deletions of 11 exon; (2) re-
arrangements !1 exon (deletions and insertions); (3) pre-
mature stop codon mutations; (4) splice signal site mu-
tations; and (5) missense mutations. Total direct costs
of the SCAIP assay, including labor and consumable sup-
plies, are estimated to be !$1,000. The actual cost of
such a clinical test will depend on the indirect and over-
head cost structures of a laboratory offering this service.
Reports of nonsynonymous polymorphisms as disease-
causing missense mutations in the dystrophinopathies
are rare. We expect that analysis of data generated by
our method will allow identification of variants at highly
conserved amino acids in patients without any other
sequence variation, leading to identification of greater
numbers of missense mutations.
The availability of rapid direct sequence analysis will
have an immediate impact on genetic counseling in the
dystrophinopathies. Because approximately one-third of
all patients with dystrophinopathy harbor de novo mu-
tations, X-linked family histories are often absent, and
testing of both known and presumptive carriers can, at
present, be performed with high reliability only if a pro-
band’s specific mutation is known. In the absence of
large-scale deletions, carrier testing relies (when possible)
on haplotype analysis. The high-quality sequence-ac-
quisition method we describe here allows ready identi-
fication of point mutations (or small-scale rearrange-
ments) in the heterozygous state and will lead to
improved genetic counseling related to dystrophinopa-
thies, as well as to other diseases to which it is applied.
Further studies to address the sensitivity of this technique
Flanigan et al.: Dystrophin Gene 939
in autosomal disorders (with only heterozygous muta-
tions) are under way.
Summary
Direct sequence analysis of large multiexon genes
from individual patient samples has heretofore been con-
sidered too labor intensive, reagent intensive, and time
consuming. As a result, many disease-related genes are
not sequenced in clinical practice. The SCAIP method is
applicable to the sequencing of any gene, allowing rapid,
economical, and efficient sequence analysis of large
multiexon genes in single patient samples.
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